Comparative Pharmacology
Head-to-head clinical analysis: CEFMAX versus CEPHALOTHIN SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFMAX versus CEPHALOTHIN SODIUM.
CEFMAX vs CEPHALOTHIN SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CEFMAX (cefepime) is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria and PBP-1a/1b in Gram-positive bacteria, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It has zwitterionic properties facilitating rapid penetration through Gram-negative outer membranes and is relatively resistant to hydrolysis by many beta-lactamases, including AmpC beta-lactamases.
Cephalothin is a first-generation cephalosporin with bactericidal activity by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins (PBPs).
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
1-2 g IV every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <10 mL/min).
Terminal elimination half-life: 0.5-1.0 hour in adults with normal renal function. In anuria, prolonged to 2.5-8 hours. Dose adjustment required for CrCl <50 mL/min.
Primarily renal (80–90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <5%.
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion). Minor biliary excretion (1-5%). Fecal elimination negligible.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic